These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 31046524)
1. The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer. Huang H; Li J; Hu WJ; Chen C; Luo HQ; Tang XD; Zhou KY; Zhong WT; Li XY Int J Biol Markers; 2019 Jun; 34(2):156-162. PubMed ID: 31046524 [TBL] [Abstract][Full Text] [Related]
2. Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. Plönes T; Krohn A; Burger M; Veelken H; Passlick B; Müller-Quernheim J; Zissel G PLoS One; 2012; 7(7):e41746. PubMed ID: 22848587 [TBL] [Abstract][Full Text] [Related]
3. CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer. Schmid S; Csanadi A; Kozhuharov N; Tchudjin M; Kayser C; Rawluk J; Passlick B; Werner M; Prasse A; Kayser G Anticancer Res; 2018 Jul; 38(7):3913-3918. PubMed ID: 29970512 [TBL] [Abstract][Full Text] [Related]
4. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer. Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483 [TBL] [Abstract][Full Text] [Related]
5. CC chemokine ligand 18(CCL18) promotes migration and invasion of lung cancer cells by binding to Nir1 through Nir1-ELMO1/DOC180 signaling pathway. Shi L; Zhang B; Sun X; Zhang X; Lv S; Li H; Wang X; Zhao C; Zhang H; Xie X; Wang Y; Zhang P Mol Carcinog; 2016 Dec; 55(12):2051-2062. PubMed ID: 26756176 [TBL] [Abstract][Full Text] [Related]
6. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer. Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320 [TBL] [Abstract][Full Text] [Related]
7. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer. Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231 [TBL] [Abstract][Full Text] [Related]
8. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group. Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482 [TBL] [Abstract][Full Text] [Related]
9. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759 [TBL] [Abstract][Full Text] [Related]
10. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer. Mo D; He F Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019 [TBL] [Abstract][Full Text] [Related]
11. Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Fei ZH; Yao CY; Yang XL; Huang XE; Ma SL Asian Pac J Cancer Prev; 2013; 14(9):5293-9. PubMed ID: 24175816 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer. Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945 [TBL] [Abstract][Full Text] [Related]
13. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607 [TBL] [Abstract][Full Text] [Related]
14. [Expression of CC-chemokine ligand 18 (CCL18) in the serum and pleural effusion of non-small-cell lung cancer patients and its regulatory effect on the differentiation of monocyte-derived dendritic cells]. Chen L; Zhou Q; Zhong F; Wang Q; Fang Y; Yang K; Guan S Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):823-7. PubMed ID: 25620478 [TBL] [Abstract][Full Text] [Related]
15. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer. Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Zohny SF; Fayed ST Med Oncol; 2010 Dec; 27(4):1246-53. PubMed ID: 19937162 [TBL] [Abstract][Full Text] [Related]
17. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342 [TBL] [Abstract][Full Text] [Related]
18. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. Jiang AG; Chen HL; Lu HY BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656 [TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
20. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]